Charles Schwab
DNTH icon

Charles Schwab’s Dianthus Therapeutics DNTH Stock Holding History

Charles Schwab’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.7M Buy
365,963
+60,523
+20% +$5.29M ﹤0.01% 1463
2026
Q1 		$25.6M Buy
305,440
+54,628
+22% +$3.16M ﹤0.01% 1594
2025
Q4 		$10.3M Buy
250,812
+57,753
+30% +$2.24M ﹤0.01% 2127
2025
Q3 		$7.6M Buy
193,059
+28,746
+17% +$735K ﹤0.01% 2239
2025
Q2 		$3.06M Sell
164,313
-3,789
-2% -$71.1K ﹤0.01% 2532
2025
Q1 		$3.05M Buy
168,102
+1,081
+0.6% +$23.8K ﹤0.01% 2474
2024
Q4 		$3.64M Buy
167,021
+1,092
+0.7% +$28.1K ﹤0.01% 2485
2024
Q3 		$4.54M Buy
165,929
+97,362
+142% +$2.71M ﹤0.01% 2422
2024
Q2 		$1.77M Buy
+68,567
New +$1.65M ﹤0.01% 2741
2023
Q3 		– Sell
-1,711
Closed -$20.7K – 3587
2023
Q2 		$20.7K Hold
1,711
– – ﹤0.01% 3556
2023
Q1 		$21.8K Hold
1,711
– – ﹤0.01% 3501
2022
Q4 		$10.8K Hold
1,711
– – ﹤0.01% 3527
2022
Q3 		$39K Buy
+1,711
New +$46.8K ﹤0.01% 3389
2022
Q2 		– Sell
-5,572
Closed -$259K – 3565
2022
Q1 		$259K Buy
5,572
+381
+7% +$20.8K ﹤0.01% 3256
2021
Q4 		$368K Hold
5,191
– – ﹤0.01% 3243
2021
Q3 		$605K Buy
5,191
+517
+11% +$60.2K ﹤0.01% 3075
2021
Q2 		$732K Buy
4,674
+1,258
+37% +$231K ﹤0.01% 3038
2021
Q1 		$648K Buy
3,416
+239
+8% +$40.2K ﹤0.01% 2999
2020
Q4 		$399K Hold
3,177
– – ﹤0.01% 3061
2020
Q3 		$346K Buy
3,177
+400
+14% +$47.4K ﹤0.01% 2986
2020
Q2 		$334K Sell
2,777
-252
-8% -$35.5K ﹤0.01% 2994
2020
Q1 		$305K Buy
3,029
+1
+0% +$185 ﹤0.01% 2889
2019
Q4 		$735K Hold
3,028
– – ﹤0.01% 2693
2019
Q3 		$498K Buy
3,028
+328
+12% +$62.3K ﹤0.01% 2804
2019
Q2 		$638K Buy
2,700
+700
+35% +$173K ﹤0.01% 2714
2019
Q1 		$527K Buy
2,000
+1,190
+147% +$205K ﹤0.01% 2746
2018
Q4 		$74K Buy
+810
New +$110K ﹤0.01% 3111

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Charles Schwab's DNTH Position: Q2 2026 in Review

Charles Schwab increased its Dianthus Therapeutics (DNTH) stake by 20% in Q2 2026, buying an estimated $5.29M and bringing the position to 365,963 shares worth $35.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1463.

Charles Schwab first reported a position in DNTH in Q4 2018 and has held it in 27 quarters since. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Charles Schwab held 365,963 shares of Dianthus Therapeutics worth $35.7M as of Q2 2026.
  • Charles Schwab bought 60,523 Dianthus Therapeutics shares in Q2 2026, an estimated $5.29M.
  • Dianthus Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1463 holding.
  • Charles Schwab first reported a position in Dianthus Therapeutics in Q4 2018 and has held it in 27 quarters since.
  • 269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.